Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
   Google Scholar
• Huang Q, Liu F, Shen J. The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights. Future Oncol. 2019;15(12):1385–1395.
   Google Scholar
• Huang Q, Liu F, Shen J. Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma. Per Med. 2019;16(4):313–323.
   Google Scholar
• Ito T, Carson WF, Cavassani KA, et al. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res. 2011;317:613–619.
   Google Scholar
• Zhu CC, Chen C, Xu ZQ, et al. CCR6 promotes tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):387–397. .
   Google Scholar
• Lu E, Su J, Zhou Y, et al. CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway. Biomed Pharmacother. 2017;85:486–492.
   Google Scholar
• Coperchini F, Croce L, Marinò M, et al. Role of chemokine receptors in thyroid cancer and immunotherapy. Endocr Relat Cancer. 2019;26(8):R465–R478. .
   Google Scholar
• Nishimura T, Fabian MR. Scanning for a unified model for translational repression by microRNAs. Embo J. 2016;35(11):1158–1159.
   Google Scholar
• Garcia-Gomez A, Rodríguez-Ubreva J, Ballestar E. Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment. Clin Immunol. 2018;196:64–71.
   Google Scholar
• Mazzoccoli L, Robaina MC, Apa AG, et al. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells. J Cancer Res Clin Oncol. 2018;144(3):483–497. .
   Google Scholar
• Go H, Jang JY, Kim CW, et al. Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2019;23:1–9.
   Google Scholar
• Wang QM, Lian GY, Song Y, et al. Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma. Cancer Gene Ther. 2019;26(7–8):195–207. .
   Google Scholar
• Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.
   Google Scholar
• Sticht C, De La Torre C, Parveen A, et al. miRWalk: an online resource for prediction of microRNA binding sites. PLoS One. 2018;13(10):e0206239.
   Google Scholar
• Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–D97.
   Google Scholar
• Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019;20(1):18.
   Google Scholar
• Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46(D1):D296–D302. .
   Google Scholar
• Paraskevopoulou MD, Georgakilas G, Kostoulas N, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013;41(Web Server issue):W169–W173. .
   Google Scholar
• Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569(7757):503–508. .
   Google Scholar
• Mei S, Qin Q, Wu Q, et al. Cistrome data browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res. 2017;45(D1):D658–D662. .
   Google Scholar
• Casper J, Zweig AS, Villarreal C, et al. The UCSC Genome Browser database: 2018 update. Nucleic Acids Res. 2018;46(D1):D762–D769. .
   Google Scholar
• Karmali R, Gordon LI. Molecular subtyping in diffuse large B cell lymphoma: closer to an approach of precision therapy. Curr Treat Options Oncol. 2017;18:11.
   Google Scholar
• Aoki-Kinoshita KF, Kanehisa M. Gene annotation and pathway mapping in KEGG. Methods Mol Biol. 2007;396:71–91.
   Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. .
   Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879–3884. .
   Google Scholar
• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–494. .
   Google Scholar
• Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122(7):1256–1265. .
   Google Scholar
• Hoadley KA, Yau C, Hinoue T, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291–304. .
   Google Scholar
• Luo X, Shi F, Qiu H, et al. Identification of potential key genes associated with diffuse large B-cell lymphoma based on microarray gene expression profiling. Neoplasma. 2017;64(6):824–833.
   Google Scholar
• Song H, Tong D, Cha Z, et al. C-X-C chemokine receptor type 5 gene polymorphisms are associated with non-Hodgkin lymphoma. Mol Biol Rep. 2012;39(9):8629–8635.
   Google Scholar
• Charbonneau B, Wang AH, Maurer MJ, et al. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother. 2013;62(9):1475–1484. .
   Google Scholar
• Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, et al. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica. 2019;104(4):778-788.
   Google Scholar
• Zhou Q, Huang L, Gu Y, et al. The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research. Cancer Biomark. 2018;21(4):925–934.
   Google Scholar
• Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014;20(10):2674–2683.
   Google Scholar
• Miloudi H, Leroy K, Jardin F, et al. STAT6 is a cargo of exportin 1: biological relevance in primary mediastinal B-cell lymphoma. Cell Signal. 2018;46:76–82.
   Google Scholar
• Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opin Investig Drugs. 2013;22(6):775–785.
   Google Scholar